Head & Neck/Thyroid Cancers
News
When cisplatin won’t do, try carboplatin in head and neck cancer
A retrospective analysis suggests carboplatin is better than cetuximab as a radiosensitizing agent.
News
Is early-onset cancer an emerging global epidemic?
“This paper ... brings to light the importance of correctable lifestyle habits that may slow the rise of early onset cancers.”
News
Despite benefits, extended-interval pembro uptake remains low
It’s possible that low uptake could stem from clinicians’ doubts about switching to an extended-interval dose, given that the FDA’s approval was...
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.
Conference Coverage
Pembro/chemo combo fails to improve event-free survival in head and neck cancer
Some trends favored chemoradiation plus pembrolizumab over chemoradiation alone, but KEYNOTE-412 failed to meet primary endpoint.
Conference Coverage
First drug for desmoid tumors: ‘Impressive’ data for nirogacestat
Nirogacestat has shown a significant improvement in progression-free survival and also a reduction in symptoms and better quality of life.
Clinical Topics & News
Trends in Palliative Care Utilization and Facility Type for Stage IV Esophageal Cancer: A National Cancer Database Analysis
Clinical Topics & News
Demographics in Early vs Late-Stage Laryngeal Squamous Cell Carcinoma: A NCDB Review
News
Nearly 30% of U.S. cancer deaths linked to smoking
Getting more people to screen for lung cancer in the United States is also important, given that only 6.6% of eligible people in 2019 received...
